Merck Eyes $32B Deal for Revolution Medicines, Stock Soars
Potential acquisition would be a major move to bolster Merck's oncology pipeline as its blockbuster Keytruda faces future patent cliffs. RVMD shares surged on the news.
Pharmaceutical giant Merck is in advanced discussions to acquire Revolution Medicines in a deal that could value the cancer-drug developer at up to $32 billion, a move that sent the biotech firm’s shares soaring in after-hours trading.
The potential acquisition, first reported by the Financial Times, would represent a significant premium to Revolution Medicines' current market capitalization of approximately $19.86 billion. Based on the reported valuation range of $28 billion to $32 billion, the offer could represent a premium of 41% to 61% for the company's shareholders.
Shares of Revolution Medicines (RVMD) jumped as much as 16% in post-market activity on the news, reflecting investor optimism about a potential deal. The stock had already closed the regular trading session up 4.56% at $107.39. Meanwhile, shares of Merck (MRK) were largely stable, trading up about 2.2% in a broadly positive market.
This potential deal highlights a critical strategic objective for major pharmaceutical companies: the race to acquire innovative assets to replenish drug pipelines. For Merck, the world's second-largest drugmaker by market value, the need is particularly acute. The company is seeking to diversify its portfolio ahead of the expected patent expiration of its top-selling cancer drug, Keytruda, in 2028. Keytruda is a foundational immunotherapy treatment that has transformed cancer care, but its eventual loss of exclusivity will create a significant revenue gap that Merck must fill.
Revolution Medicines presents a compelling solution. The Redwood City, California-based company is at the forefront of developing novel, targeted therapies for cancers driven by the RAS and mTOR signaling pathways. These pathways have long been considered among the most difficult to target, often referred to as 'undruggable.'
Revolution Medicines' innovative pipeline, which includes lead candidates like daraxonrasib and zoldonrasib, has shown significant promise in clinical trials for treating lung and pancreatic cancers. The U.S. Food and Drug Administration recently granted Breakthrough Therapy Designation to one of its programs, underscoring the potential of its science. Acquiring Revolution Medicines would give Merck direct access to this highly sought-after pipeline of next-generation cancer therapies.
The discussions are reportedly ongoing, and a final agreement has not been reached. It has also been reported that other large pharmaceutical companies have shown interest in Revolution Medicines, which could potentially lead to a competitive bidding situation. Neither Merck nor Revolution Medicines have issued an official public comment on the matter.
For investors, the potential acquisition represents a major validation of Revolution Medicines' platform and a significant return. The company’s stock has seen a remarkable run, trading as low as $29.17 within the last year, and the proposed deal would crystallize substantial gains for its backers. Analyst sentiment on the stock is overwhelmingly positive, with 20 'buy' or 'strong buy' ratings and no 'sell' ratings, according to market data.
The potential acquisition of Revolution Medicines is part of a broader trend of M&A activity in the biopharmaceutical sector. As large-cap companies face patent cliffs and have substantial cash reserves, they are increasingly looking to smaller, innovative biotech firms to acquire cutting-edge technology and future growth drivers. If completed, the Merck-Revolution Medicines deal would be one of the largest biotech acquisitions of the year, underscoring the high value placed on promising new cancer treatments.